Back to results
US 2017/0319551 A1Published application
Nuclear transport modulators and uses thereof
AssigneeKaryopharm Therapeutics Inc.
InventorsVincent P. Sandanayaka, Sharon Shechter, Sharon Shacham, Dilara McCauley, Erkan Baloglu
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
Claims23
A compound of formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is selected from hydrogen and C1-C4 alkyl;
- R2 is selected from O and S;
- and
- R3 is selected from —N(R4)—(C3-C6 cycloalkyl), —C1-C6 alkyl, —(C0-C4 alkylene)-heterocyclyl, and —(C0-C4 alkylene)-heteroaryl, wherein any alkyl, alkylene, heterocyclyl, and heteroaryl portion of R3 is optionally and independently substituted;
- and
- R4 is selected from hydrogen and C1-C4 alkyl.
4 more elements
A compound represented by any one of the structural formulas set forth below:
- Cmpd No.
- Compound Structure
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- or a pharmaceutically acceptable salt thereof.
15 more elements
23-31. (canceled)
Dependencies are inferred from the claim text.